Ligand Pharmaceuticals (LGND) SEC Filings & 10K Form

$86.06
+1.04 (+1.22%)
(As of 05/17/2024 06:55 PM ET)

Recent Ligand Pharmaceuticals SEC Filings

DateFilerForm TypeView
05/17/2024
6:59 PM
Espinoza Octavio (Reporting)
Ligand Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
05/17/2024
7:00 PM
Gray Nancy Ryan (Reporting)
Ligand Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
05/17/2024
4:45 PM
Espinoza Octavio (Reporting)
Ligand Pharmaceuticals (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
05/16/2024
4:39 PM
Espinoza Octavio (Reporting)
Ligand Pharmaceuticals (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
05/15/2024
6:34 PM
Korenberg Matthew E (Reporting)
Ligand Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
05/15/2024
5:01 PM
Espinoza Octavio (Reporting)
Ligand Pharmaceuticals (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
05/15/2024
1:45 PM
Korenberg Matthew E (Reporting)
Ligand Pharmaceuticals (Subject)
Form 144/A
05/14/2024
6:42 PM
Korenberg Matthew E (Reporting)
Ligand Pharmaceuticals (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
05/13/2024
5:14 PM
Korenberg Matthew E (Reporting)
Ligand Pharmaceuticals (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
05/13/2024
4:32 PM
Ligand Pharmaceuticals (Issuer)
Reardon Andrew (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
05/09/2024
5:03 PM
Gray Nancy Ryan (Reporting)
Ligand Pharmaceuticals (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
05/09/2024
5:06 PM
Ligand Pharmaceuticals (Subject)
Reardon Andrew (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
05/09/2024
3:11 PM
Ligand Pharmaceuticals (Filer)
Form DEFA14A
05/07/2024
6:36 AM
Ligand Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
05/02/2024
5:07 PM
Aryeh Jason (Reporting)
Ligand Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
04/26/2024
5:35 PM
KOZARICH JOHN W (Reporting)
Ligand Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
03/27/2024
4:47 PM
Davis Todd C (Reporting)
Ligand Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
03/07/2024
12:27 PM
Ligand Pharmaceuticals (Issuer)
Sabba Stephen L (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
03/06/2024
4:28 PM
Aryeh Jason (Reporting)
Ligand Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
03/05/2024
5:12 PM
Ligand Pharmaceuticals (Subject)
Sabba Stephen L (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
02/29/2024
5:49 PM
Davis Todd C (Reporting)
Ligand Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
02/29/2024
5:50 PM
Espinoza Octavio (Reporting)
Ligand Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
02/29/2024
5:50 PM
Korenberg Matthew E (Reporting)
Ligand Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
02/29/2024
5:50 PM
Ligand Pharmaceuticals (Issuer)
Reardon Andrew (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
02/29/2024
3:49 PM
Espinoza Octavio (Reporting)
Ligand Pharmaceuticals (Subject)
Form 144/A
02/29/2024
3:16 PM
Ligand Pharmaceuticals (Filer)
Form 10-K
Annual report pursuant to Section 13 or 15(d)  
02/28/2024
5:05 PM
Gray Nancy Ryan (Reporting)
Ligand Pharmaceuticals (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
02/28/2024
4:43 PM
Espinoza Octavio (Reporting)
Ligand Pharmaceuticals (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
02/27/2024
6:24 AM
Ligand Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
02/16/2024
7:10 PM
Davis Todd C (Reporting)
Ligand Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
02/16/2024
7:10 PM
Espinoza Octavio (Reporting)
Ligand Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
02/16/2024
7:10 PM
Korenberg Matthew E (Reporting)
Ligand Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
02/16/2024
7:10 PM
Ligand Pharmaceuticals (Issuer)
Reardon Andrew (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
02/14/2024
5:26 AM
Ligand Pharmaceuticals (Subject)
MACQUARIE GROUP LTD (Filed by)
Form SC 13G
02/13/2024
2:39 PM
JANUS HENDERSON GROUP PLC (Filed by)
Ligand Pharmaceuticals (Subject)
Form SC 13G/A
02/12/2024
6:42 PM
GOLDMAN SACHS GROUP INC (Filed by)
GOLDMAN SACHS GROUP INC (Filed by)
Ligand Pharmaceuticals (Subject)
Form SC 13G
01/22/2024
1:03 PM
BlackRock Inc. (Filed by)
Ligand Pharmaceuticals (Subject)
Form SC 13G/A
01/04/2024
3:07 PM
Korenberg Matthew E (Reporting)
Ligand Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
01/04/2024
3:07 PM
Ligand Pharmaceuticals (Issuer)
Reardon Andrew (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
12/06/2023
2:27 PM
Korenberg Matthew E (Reporting)
Ligand Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
12/06/2023
2:27 PM
Espinoza Octavio (Reporting)
Ligand Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
This Apple-like Innovator is Revolutionizing Healthcare (Ad)

AI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.

Click here to learn more about the booming eHealth industry
12/01/2023
7:25 AM
Ligand Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
10/18/2023
8:03 AM
Ligand Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
10/03/2023
3:36 PM
Espinoza Octavio (Reporting)
Ligand Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
09/27/2023
7:38 AM
Ligand Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
09/26/2023
3:41 PM
Ligand Pharmaceuticals (Issuer)
Zimmermann Martine (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
09/25/2023
5:12 PM
Ligand Pharmaceuticals (Issuer)
Zimmermann Martine (Reporting)
Form 3
Initial statement of beneficial ownership of securities  
09/25/2023
3:44 PM
Davis Todd C (Reporting)
Ligand Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
09/18/2023
4:26 PM
Ligand Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
08/14/2023
3:20 PM
Ligand Pharmaceuticals (Issuer)
Reardon Andrew (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
07/10/2023
5:42 PM
Espinoza Octavio (Reporting)
Ligand Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
07/10/2023
5:42 PM
Korenberg Matthew E (Reporting)
Ligand Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
06/21/2023
8:28 AM
Ligand Pharmaceuticals (Issuer)
Sabba Stephen L (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/13/2023
5:52 PM
Davis Todd C (Reporting)
Ligand Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
06/13/2023
5:53 PM
Haas Jason (Reporting)
Ligand Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
06/13/2023
5:54 PM
Aryeh Jason (Reporting)
Ligand Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
06/13/2023
5:54 PM
KOZARICH JOHN W (Reporting)
Ligand Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
06/13/2023
5:55 PM
LAMATTINA JOHN L (Reporting)
Ligand Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
06/13/2023
5:55 PM
Gray Nancy Ryan (Reporting)
Ligand Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
(Data available from 1/1/2016 forward)


Related Companies and Tools

This page (NASDAQ:LGND) was last updated on 5/20/2024 by MarketBeat.com Staff

From Our Partners